Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects.
paper
Cited
Public
Unavailable
- Authors
- Gelernter, J; Kranzler, H; Cubells, J
- Year
- 1999
- Journal
- Molecular psychiatry
- PMID
- 10523821
- DOI
- 10.1038/sj.mp.4000556
The gene encoding the mu opioid receptor, OPRM1, contains at least two polymorphisms affecting protein sequence in exon 1, Ala6Val and Asp40Asn. In previous studies, each variant has been reported to be associated with some form of drug dependence. Although past reports have not been consistent, they have also not considered comparable populations. The goals of the present study were to delineate allele and haplotype frequencies of these variants in a range of populations, and in drug- or alcohol-dependent subjects deriving from some of those populations. We developed new PCR-RFLP methods to detect both of these polymorphisms and studied them in control and substance-dependent populations of African American (AA), European American (EA) and Hispanic origin, and in a series of populations differing in geographic origin (Japanese, Ethiopians, Bedouins, and Ashkenazi Jews), 891 subjects overall. We designed primers flanking the DNA segment containing both polymorphisms, each primer creating a different artificial restriction site, such that a single PCR reaction can be completed, then divided, and the PCR product digested with either of two enzymes to reveal both polymorphisms. We found that allele frequencies for both polymorphic systems were significantly different between AA and EA subjects, and there was significant heterogeneity among the more extensive set of populations. Furthermore, there were no significant differences in allele frequency by diagnosis; that is, neither polymorphism appears to be a direct risk factor for substance dependence. Finally, we demonstrated linkage disequilibrium between the two exon 1 markers, and a previously described short tandem repeat (STR) marker.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Cannabinoids and Multiple Sclerosis: A Critical Analysis of Therapeutic Potentials and Safety Concerns. | Nouh RA et al. | β | 2023 | β |
| Using naltrexone to validate a human laboratory test system to screen new medications for alcoholism (TESMA)- a randomized clinical trial. | Spreer M et al. | β | 2023 | β |
| Associations of the A118G OPRM1 polymorphism with sociotropy and interpersonal sensitivity. | Suzuki A et al. | β | 2022 | β |
| Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction. | Kember RL et al. | β | 2022 | β |
| Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. | Schacht JP et al. | β | 2022 | β |
| The A118G single-nucleotide polymorphism in OPRM1 is a risk factor for asthma severity. | Kawakami K et al. | β | 2022 | β |
| A systems omics-based approach to decode substance use disorders and neuroadaptations. | Veerappa A et al. | β | 2021 | β |
| Genetic susceptibility of opioid receptor genes polymorphism to drug addiction: A candidate-gene association study. | Al-Eitan LN et al. | β | 2021 | β |
| Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A Genome-Wide Association Study. | Zhou H et al. | β | 2020 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Mu-Opioid Receptor Polymorphism Moderates Sensitivity to Parental Behaviors During Characterization of Personality Traits. | Noto K et al. | β | 2020 | β |
| Neural and sociocultural mediators of ethnic differences in pain. | Losin EAR et al. | β | 2020 | β |
| Social withdrawal: An initially adaptive behavior that becomes maladaptive when expressed excessively. | Ike KGO et al. | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| The Streetlight Effect: Reappraising the Study of Addiction in Light of the Findings of Genome-wide Association Studies. | Hall FS et al. | β | 2020 | β |
| Associations among the opioid receptor gene (<i>OPRM1</i>) A118G polymorphism, psychiatric symptoms, and quantitative EEG in Korean males with gambling disorder: A pilot study. | Kim KM et al. | β | 2019 | β |
| Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. | Hansson AC et al. | β | 2019 | β |
| GWAS including 82,707 subjects identifies functional coding variant in <i>OPRM1</i> gene associated with opioid use disorder | Zhou H et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | β | 2019 | β |
| Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry. | Popova D et al. | β | 2019 | β |
| The association between the OPRM1 A118G polymorphism and addiction in a Turkish population. | TΓΌrkan H et al. | β | 2019 | β |
| The influence of the OPRM1 (A118G) polymorphism on behavioral and neural correlates of aggression in healthy males. | Weidler C et al. | β | 2019 | β |
| Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach. | Sluiter RL et al. | β | 2018 | β |
| Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis. | Ahmed M et al. | β | 2018 | β |
| Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms. | Henderson-Redmond AN et al. | β | 2018 | β |
| Parental overcontrol x OPRM1 genotype interaction predicts school-aged children's sympathetic nervous system activation in response to performance challenge. | Partington LC et al. | β | 2018 | β |
| Pharmacogenetics of Cannabinoids. | Hryhorowicz S et al. | β | 2018 | β |
| Convergent Balancing Selection on the Mu-Opioid Receptor in Primates. | Sweeney CG et al. | β | 2017 | β |
| Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment. | Chatti I et al. | β | 2017 | β |
| Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism. | Browne CA et al. | β | 2017 | β |
| Low ΞΌ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. | Hermann D et al. | β | 2017 | β |
| Spicy Food Preference and Risk for Alcohol Dependence in Korean. | Park JH et al. | β | 2017 | β |
| The Role of Chronic Psychosocial Stress in Explaining Racial Differences in Stress Reactivity and Pain Sensitivity. | Gordon JL et al. | β | 2017 | β |
| A gene-by-sex interaction for nicotine reward: evidence from humanized mice and epidemiology. | Bernardi RE et al. | β | 2016 | β |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | β | 2016 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism. | Henderson-Redmond AN et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| Translational Research on Nicotine Dependence. | Falcone M et al. | β | 2016 | β |
| A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. | Bilbao A et al. | β | 2015 | β |
| Challenges for opioid receptor nomenclature: IUPHAR Review 9. | Cox BM et al. | β | 2015 | β |
| Co-development of early adolescent alcohol use and depressive feelings: The role of the mu-opioid receptor A118G polymorphism. | Kleinjan M et al. | β | 2015 | β |
| Human population genetic structure detected by pain-related mu opioid receptor gene polymorphisms. | LΓ³pez Soto EJ et al. | β | 2015 | β |
| Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study. | Pal R et al. | β | 2015 | β |
| Mouse model of OPRM1 (A118G) polymorphism increases sociability and dominance and confers resilience to social defeat. | Briand LA et al. | β | 2015 | β |
| Association between single nucleotide polymorphisms in the OPRM1 gene and intraoperative remifentanil consumption in northern Chinese women. | Liu J et al. | β | 2014 | β |
| Pharmacogenetics of the G protein-coupled receptors. | Thompson MD et al. | β | 2014 | β |
| Dual growth of adolescent smoking and drinking: evidence for an interaction between the mu-opioid receptor (OPRM1) A118G polymorphism and sex. | Kleinjan M et al. | β | 2013 | β |
| Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? | Hall FS et al. | β | 2013 | β |
| Improving clinical outcomes for naltrexone as a management of problem alcohol use. | Hulse GK | β | 2013 | β |
| Influence of mu-opioid receptor variant on morphine use and self-rated pain following abdominal hysterectomy. | Sia AT et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study. | Chen YT et al. | β | 2013 | β |
| OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. | Haerian BS et al. | β | 2013 | β |
| Recent developments in the study of opioid receptors. | Cox BM | β | 2013 | β |
| The ΞΌ-opioid receptor and treatment response to naltrexone. | Thorsell A | β | 2013 | β |
| ΞΌ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption. | Rouvinen-LagerstrΓΆm N et al. | β | 2013 | β |
| A118G mu opioid receptor polymorphism among drug addicts in Malaysia. | Nagaya D et al. | β | 2012 | β |
| A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. | Crystal HA et al. | β | 2012 | β |
| A quantitative review of ethnic group differences in experimental pain response: do biology, psychology, and culture matter? | Rahim-Williams B et al. | β | 2012 | β |
| Association of Β΅-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. | Chamorro AJ et al. | β | 2012 | β |
| A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. | Verhagen M et al. | β | 2012 | β |
| Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. | Fucito LM et al. | β | 2012 | β |
| Estimating ancestral proportions in a multi-ethnic US sample: implications for studies of admixed populations. | Levran O et al. | β | 2012 | β |
| Geographic differences in perioperative opioid administration in children. | Rabbitts JA et al. | β | 2012 | β |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | β | 2012 | β |
| Modeling borderline personality disorder based on the neurobehavioral foundation of major personality traits. | Depue RA et al. | β | 2012 | β |
| Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. | Al-Eitan LN et al. | β | 2012 | β |
| Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. | Ray LA et al. | β | 2012 | β |
| Pharmacogenomics of opioids and perioperative pain management. | Sadhasivam S et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The promise of pharmacogenetics in labor analgesiaβ¦tantalizing, but not there yet. | Wong CA | β | 2012 | β |
| The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. | Ray LA et al. | β | 2012 | β |
| Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects. | Kolesnikov Y et al. | β | 2011 | β |
| Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. | Ray R et al. | β | 2011 | β |
| Molecular mechanisms of opioid receptor-dependent signaling and behavior. | Al-Hasani R et al. | β | 2011 | β |
| Neurogenetic and experiential processes underlying major personality traits: implications for modelling personality disorders. | Depue RA et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. | Setiawan E et al. | β | 2011 | β |
| Initial evidence of an association between OPRM1 and adolescent alcohol misuse. | Miranda R et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. | Deb I et al. | β | 2010 | β |
| Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. | Ray LA et al. | β | 2010 | β |
| The genetics of pain: implications for evaluation and treatment of spinal disease. | Kim DH et al. | β | 2010 | β |
| The role of microRNAs in drug addiction: a big lesson from tiny molecules. | Pietrzykowski AZ | β | 2010 | β |
| A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. | Kim SG et al. | β | 2009 | β |
| Candidate genes for cannabis use disorders: findings, challenges and directions. | Agrawal A et al. | β | 2009 | β |
| Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. | Tan EC et al. | β | 2009 | β |
| Genetic, environmental, and epigenetic factors in the development of personality disturbance. | Depue RA | β | 2009 | β |
| Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. | Coller JK et al. | β | 2009 | β |
| Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. | Mague SD et al. | β | 2009 | β |
| OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. | Oroszi G et al. | β | 2009 | β |
| Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. | Wu WD et al. | β | 2009 | β |
| Role of the HPA axis and the A118G polymorphism of the mu-opioid receptor in stress-induced drinking behavior. | Pratt WM et al. | β | 2009 | β |
| The interaction of reward genes with environmental factors in contribution to alcoholism in mexican americans. | Du Y et al. | β | 2009 | β |
| A functional polymorphism of the micro-opioid receptor gene is associated with completed suicides. | Hishimoto A et al. | β | 2008 | β |
| An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. | Anton RF et al. | β | 2008 | β |
| Approach to the genetics of alcoholism: a review based on pathophysiology. | KΓΆhnke MD | β | 2008 | β |
| Beta-endorphin and drug-induced reward and reinforcement. | Roth-Deri I et al. | β | 2008 | β |
| Genetic approaches to addiction: genes and alcohol. | Ducci F et al. | β | 2008 | β |
| Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. | Landau R et al. | β | 2008 | β |
| G protein-coupled receptor pharmacogenetics. | Thompson MD et al. | β | 2008 | β |
| Markers in the 5'-region of GABRG1 associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent GABRA2 gene. | Covault J et al. | β | 2008 | β |
| Pharmacogenetic treatments for drug addiction: alcohol and opiates. | Haile CN et al. | β | 2008 | β |
| The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity. | Bruehl S et al. | β | 2008 | β |
| The opioid peptides enkephalin and beta-endorphin in alcohol dependence. | Racz I et al. | β | 2008 | β |
| Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. | Johnson BA | β | 2008 | β |
| A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. | Kapur S et al. | β | 2007 | β |
| Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. | Glatt SJ et al. | β | 2007 | β |
| Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism. | Margas W et al. | β | 2007 | β |
| Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. | Hernandez-Avila CA et al. | β | 2007 | β |
| The opioid system in alcohol and drug dependence: family-based association study. | Xuei X et al. | β | 2007 | β |
| The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. | Kroslak T et al. | β | 2007 | β |
| Anger regulation style, postoperative pain, and relationship to the A118G mu opioid receptor gene polymorphism: a preliminary study. | Bruehl S et al. | β | 2006 | β |
| Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. | Zhang H et al. | β | 2006 | β |
| Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. | Arias A et al. | β | 2006 | β |
| Association of mu-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. | Nishizawa D et al. | β | 2006 | β |
| Genetic moderators of naltrexone's effects on alcohol cue reactivity. | McGeary JE et al. | β | 2006 | β |
| Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. | Ide S et al. | β | 2006 | β |
| Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. | Drakenberg K et al. | β | 2006 | β |
| New findings on the genetic influences on alcohol use and dependence. | Higuchi S et al. | β | 2006 | β |
| Perspectives on current directions in the neurobiology of addiction disorders relevant to genetic risk factors. | Hurd YL | β | 2006 | β |
| Pharmacogenetics of opioid receptors and addiction. | Mayer P et al. | β | 2006 | β |
| Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. | LΓΆtsch J et al. | β | 2006 | β |
| Symbiotic relationship of pharmacogenetics and drugs of abuse. | Rutter JL | β | 2006 | β |
| Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. | Oslin DW et al. | β | 2006 | β |
| The mu-opioid receptor gene and smoking initiation and nicotine dependence. | Zhang L et al. | β | 2006 | β |
| The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. | Chong RY et al. | β | 2006 | β |
| Are mu-opioid receptor polymorphisms important for clinical opioid therapy? | LΓΆtsch J et al. | β | 2005 | β |
| Genetic determinants of addiction to opioids and cocaine. | Saxon AJ et al. | β | 2005 | β |
| How individual sensitivity to opiates can be predicted by gene analyses. | Ikeda K et al. | β | 2005 | β |
| Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. | Bart G et al. | β | 2005 | β |
| Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. | Smith RJ et al. | β | 2005 | β |
| Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. | Kreek MJ et al. | β | 2005 | β |
| Pharmacogenetics: implications for obstetric anesthesia. | Landau R | β | 2005 | β |
| The contribution of genetics to addiction therapy approaches. | Edenberg HJ et al. | β | 2005 | β |
| The G protein-coupled receptors: pharmacogenetics and disease. | Thompson MD et al. | β | 2005 | β |
| A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. | Ray LA et al. | β | 2004 | β |
| Association of functional opioid receptor genotypes with alcohol dependence in Koreans. | Kim SG et al. | β | 2004 | β |
| Association of polymorphisms in nicotinic acetylcholine receptor alpha 4 subunit gene (CHRNA4), mu-opioid receptor gene (OPRM1), and ethanol-metabolizing enzyme genes with alcoholism in Korean patients. | Kim SA et al. | β | 2004 | β |
| Comprehensive mu-opioid-receptor genotyping by pyrosequencing. | Skarke C et al. | β | 2004 | β |
| Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. | Loh el W et al. | β | 2004 | β |
| Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. | Kreek MJ et al. | β | 2004 | β |
| Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. | Ide S et al. | β | 2004 | β |
| Genes associated with addiction: alcoholism, opiate, and cocaine addiction. | Kreek MJ et al. | β | 2004 | β |
| Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. | LΓΆtsch J et al. | β | 2004 | β |
| Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. | Urraca N et al. | β | 2004 | β |
| Opioids and alcoholism. | Oswald LM et al. | β | 2004 | β |
| The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. | Lerman C et al. | β | 2004 | β |
| A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. | Oslin DW et al. | β | 2003 | β |
| A genetic association study of the mu opioid receptor and severe opioid dependence. | Crowley JJ et al. | β | 2003 | β |
| Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. | Compton P et al. | β | 2003 | β |
| Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). | Hernandez-Avila CA et al. | β | 2003 | β |
| Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained vs control subjects. | Schluger JH et al. | β | 2003 | β |
| Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. | Luo X et al. | β | 2003 | β |
| Introducing a new recruitment approach to sample collection for genetic association studies in opioid dependence. | Franke P et al. | β | 2003 | β |
| Mu opioid receptor gene polymorphism and neuroleptic-induced tardive dyskinesia in patients with schizophrenia. | Tan EC et al. | β | 2003 | β |
| Neuropeptide gene polymorphisms and human behavioural disorders. | Inui A | β | 2003 | β |
| Pharmacogenomics of alcohol response and addiction. | Enoch MA | β | 2003 | β |
| A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. | Schinka JA et al. | β | 2002 | β |
| Association of mu-opioid receptor subunit gene and idiopathic generalized epilepsy. | Wilkie H et al. | β | 2002 | β |
| Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants. | Xin L et al. | β | 2002 | β |
| Lack of association of a single-nucleotide polymorphism of the mu-opioid receptor gene with anxiety-related traits: results from a cross-sectional study of adults and a longitudinal study of children. | Jorm AF et al. | β | 2002 | β |
| Opioid receptor polymorphisms and opioid abuse. | Lee NM et al. | β | 2002 | β |
| The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity. | Trujillo KA | β | 2002 | β |
| Allelic and somatic variations in the endogenous opioid system of humans. | Mayer P et al. | β | 2001 | β |
| Genetic variations in human G protein-coupled receptors: implications for drug therapy. | Sadee W et al. | β | 2001 | β |
| Morphine tolerance in mice is independent of polymorphisms in opioid receptor sequences. | Gant TM et al. | β | 2001 | β |
| Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. | Franke P et al. | β | 2001 | β |
| Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. | Wang D et al. | β | 2001 | β |
| The genetics of alcoholism and alcohol abuse. | Enoch MA et al. | β | 2001 | β |
| Endogenous opiates: 1999. | Vaccarino AL et al. | β | 2000 | β |
| Genetic vulnerability to drug abuse. | Duaux E et al. | β | 2000 | β |
| Opioid receptor and peptide gene polymorphisms: potential implications for addictions. | LaForge KS et al. | β | 2000 | β |
| The opioid receptor system and alcoholism: a genetic perspective. | Town T et al. | β | 2000 | β |